



YELLOW CARD FOR PATIENT SAFETY

S. R. Dhopate, P. R. Kale, S. M. Rathod, N. S. Bhajipale

S.G.S.P.S. Institute of Pharmacy, Akola, Maharashtra, India – 444004

ABSTRACT

The yellow card scheme is an early warning system for the identification of previously unrecognized Adverse drug Reaction and enable the MHRA (Medicines and Healthcare product Regulatory agency) to identify risk factors outcome of Adverse drug Reaction and other issue that may affect Clinical Management; including the safer use of medicines to protect patients from a voidable harm. Adverse drug reactions (ADR's) are Unwanted or Harmful side effect that occurs after administration of any medicine. The public has been able to Report an ADR since 2005 through the Yellow Card Scheme (YCS). In 2014-2015 patients were responsible for 147 reports send to the yellow card centre in wales. There is barely any evaluation of existing patient reporting Schemes have reported on the Numbers and nature of reports but none seemed to have reported on patient experience. There was a 14% responsible rate, evenly distributed between gender and those with a limiting long term illness. The mean age of responsible was 50. Two participants were qualifies health care professionals, one being a pharmacist Twenty eight participants had experienced an ADR themselves however, only 4% of participants had reported their ADR through the yellow card scheme (YCS). 96% of respondents said if they were to experience an ADR in the future they would report it to their doctor, 15% said they would report an ADR to the MHRA.16% had heard of the YCS, only 2 had reported an ADR through the scheme. 56% requested to learn more about the YCS while 58% preferred the method of learning to be via online method.

KEYWORDS: yellow card, MHRA, ADR.

Indian Research Journal of Pharmacy and Science; 24(2020)2144;
Journal Home Page: <https://www.irjps.in>